Association of circulating proprotein convertase subtilisin/kexin type 9 concentration with coagulation abnormalities in patients with primary membranous nephropathy

References

• Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):1–9.
   PubMed Web of Science ®Google Scholar
• Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a midwest pediatric nephrology consortium (MWPNC) study. J Pediatr. 2009;155(1):105–110, 110 e1.
   PubMed Web of Science ®Google Scholar
• Shinkawa K, Yoshida S, Seki T, et al. Risk factors of venous thromboembolism in patients with nephrotic syndrome: a retrospective cohort study. Nephrol Dial Transplant. 2021;36(7):1199–1206.
   Web of Science ®Google Scholar
• Kayali F, Najjar R, Aswad F, et al. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med. 2008;121(3):226–230.
   PubMed Web of Science ®Google Scholar
• Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18(8):2221–2225.
   PubMed Web of Science ®Google Scholar
• Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost. 1997;23(3):271–280.
   PubMed Web of Science ®Google Scholar
• Kuipers S, Cannegieter SC, Doggen CJM, et al. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood. 2009;113(9):2064–2069.
   PubMed Web of Science ®Google Scholar
• Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113(8):636–642.
   PubMed Web of Science ®Google Scholar
• Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513–520.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156.
   PubMed Web of Science ®Google Scholar
• Zhang D-W, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282(25):18602–18612.
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101(18):7100–7105.
   PubMed Web of Science ®Google Scholar
• Jin K, Park B-S, Kim Y-W, et al. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014;63(4):584–589.
   PubMed Web of Science ®Google Scholar
• Kwakernaak AJ, Lambert G, Slagman MCJ, et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis. 2013;226(2):459–465.
   PubMed Web of Science ®Google Scholar
• Molina-Jijon E, Gambut S, Macé C, et al. Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome. Kidney Int. 2020;98(6):1449–1460.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang Q, Wang J, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency is protective against venous thrombosis in mice. Sci Rep. 2017;7(1):14360.
   PubMedGoogle Scholar
• Dwivedi DJ, Grin PM, Khan M, et al. Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis. Shock. 2016;46(6):672–680.
   PubMed Web of Science ®Google Scholar
• Peng J, et al. Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thromb J. 2021;19(1):90.
   PubMed Web of Science ®Google Scholar
• Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8(1):2267.
   PubMedGoogle Scholar
• Bovenschen N, Mertens K, Hu L, et al. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood. 2005;106(3):906–912.
   PubMed Web of Science ®Google Scholar
• Basiak M, et al. Effect of PCSK9 inhibitors on hemostasis in patients with isolated hypercholesterolemia. J Clin Med. 2022;11(9):2542.
   PubMed Web of Science ®Google Scholar
• Grover SP, Mackman N. Tissue factor in atherosclerosis and atherothrombosis. Atherosclerosis. 2020;307:80–86.
   PubMed Web of Science ®Google Scholar
• Wang M, et al. Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus. J Geriatr Cardiol. 2016;13(4):312–315.
   PubMedGoogle Scholar
• Xu X, Wang G, Chen N, et al. Long-Term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):3739–3746.
   PubMed Web of Science ®Google Scholar
• Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190–195.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes Glomerular Diseases Work. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276.
   PubMedGoogle Scholar
• Simion C, Campello E, Bensi E, et al. Use of glucocorticoids and risk of venous thromboembolism: a narrative review. Semin Thromb Hemost. 2021;47(6):654–661.
   PubMedGoogle Scholar
• Citak A, Emre S, Sâirin A, et al. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. 2000;14(2):138–142.
   PubMed Web of Science ®Google Scholar
• Ozkaya O, Bek K, Fişgin T, et al. Low protein Z levels in children with nephrotic syndrome. Pediatr Nephrol. 2006;21(8):1122–1126.
   PubMed Web of Science ®Google Scholar
• Cruz C, Juárez-Nicolás F, Tapia E, et al. Abnormalities of coagulation in experimental nephrotic syndrome. Nephron. 1994;68(4):489–496.
   PubMed Web of Science ®Google Scholar
• Huang M-J, Wei R-B, Wang Z-C, et al. Mechanisms of hypercoagulability in nephrotic syndrome associated with membranous nephropathy as assessed by thromboelastography. Thromb Res. 2015;136(3):663–668.
   PubMed Web of Science ®Google Scholar
• Odimegwu CL, Ikefuna AN, Okafor HU, et al. Haemostatic profile of children with nephrotic syndrome attending university of Nigeria teaching hospital Ituku-Ozalla, Nigeria. BMC Nephrol. 2022;23(1):274.
   PubMed Web of Science ®Google Scholar
• Loscalzo J. Venous thrombosis in the nephrotic syndrome. N Engl J Med. 2013;368(10):956–958.
   PubMed Web of Science ®Google Scholar
• Haas ME, Levenson AE, Sun X, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic Syndrome-Associated hypercholesterolemia. Circulation. 2016;134(1):61–72.
   PubMed Web of Science ®Google Scholar
• Shen H, Feng S, Lu Y, et al. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome. Ren Fail. 2020;42(1):405–412.
   PubMed Web of Science ®Google Scholar
• Doiron S, et al. Association between circulating PCSK9 and proteinuria in nephrotic syndrome: a cross-sectional study. Clin Biochem. 2022;109–110:51–56.
   PubMed Web of Science ®Google Scholar